EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board

Camila B Xavier iD, Rudinei Link, Leonília Abreu, Fabiana Bettoni, Fabiane Marson, Pedro A F Galante, Cibele Masotti, Mariane T Amano, Vinicius de Molla, Anamaria A Camargo, Paula F Asprino, Jorge Sabbaga

The Oncologist · 2023

DOI: 10.1093/oncolo/oyad105 ↗

Kurz gefasst

Fallbericht in der Zeitschrift The Oncologist, 2023. Verfasst von Camila B Xavier und 11 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Center, Hospital Sírio-Libanês, São Paulo, SP, Brazil. Hauptthemen laut MEDLINE: Genetic Predisposition to Disease, Li-Fraumeni Syndrome. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Li-Fraumeni syndrome (LFS) is a pan-cancer predisposition syndrome caused by germline pathogenic variants in the gene TP53. The interpretation of TP53 variants in clinical scenarios outside the classic LFS criteria may be challenging. Here, we report a patient affected by 2 primary cancers at later ages, who harbored a likely pathogenic TP53 at low allele frequency detected in a blood sample.

Methods

The Molecular Tumor Board committee at our institution revisited the case of a patient who was enrolled in a research protocol for the investigation of genetic conditions associated with neuroendocrine tumors. Clinical, familial, and molecular data were reviewed. The patient received germline testing using a next generation sequencing multi-gene panel and was incidentally found to harbor a TP53 likely pathogenic variant, with 22% of variant allele fraction. Additional samples, including a second blood sample, oral swab, and saliva, were collected for DNA analysis. A new TP53 sequencing round was performed with the attempt to distinguish between a true constitutional germline variant and a somatically acquired variant due to aberrant clonal expansion of bone marrow precursors.

Results

Patient’s personal and familial history of cancer did not meet classic nor Chompret LFS criteria. Environmental risk factors for cancer were identified, such as alcohol abuse and tobacco exposure. The TP53 variant initially found in the next-generation sequencing was confirmed by Sanger sequencing in the previous DNA sample extracted from blood for the first analysis and in a second blood sample collected 6 years later. The TP53 variant was not detected in the DNA extracted from the oral swab and saliva samples.

Conclusion

Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic Predisposition to DiseaseLi-Fraumeni SyndromeHumansClonal HematopoiesisGenetic TestingTumor Suppressor Protein p53Germ-Line MutationGerm Cells

Substanzen

Tumor Suppressor Protein p53TP53 protein, human

Autor:innen und Institutionen

  • Oncology Center, Hospital Sírio-Libanês, São Paulo, SP, Brazil.
  • Molecular Oncology Center, Hospital Sírio-Libanês, São Paulo, SP, Brazil.
  • Hematology Center, Hospital Sírio-Libanês, São Paulo, SP, Brazil.
  • Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, SP, Brazil.

ORCID-Profile: Camila B Xavier

Förderung

  • Fundação de Amparo à Pesquisa do Estado de São Paulo

Zitieren

APA

Xavier, C. B., Link, R., Abreu, L., Bettoni, F., Marson, F., Galante, P. A. F., Masotti, C., Amano, M. T., de Molla, V., Camargo, A. A., Asprino, P. F., & Sabbaga, J. (2023). Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board. The Oncologist. https://doi.org/10.1093/oncolo/oyad105

Vancouver

Xavier CB, Link R, Abreu L, Bettoni F, Marson F, Galante PAF, et al. Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board. The Oncologist. 2023. doi:10.1093/oncolo/oyad105

BibTeX
@article{Xavier2023,
  author = {Xavier, Camila B and Link, Rudinei and Abreu, Leonília and Bettoni, Fabiana and Marson, Fabiane and Galante, Pedro A F and Masotti, Cibele and Amano, Mariane T and de Molla, Vinicius and Camargo, Anamaria A and Asprino, Paula F and Sabbaga, Jorge},
  title = {Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board},
  journal = {The Oncologist},
  year = {2023},
  doi = {10.1093/oncolo/oyad105}
}
Kostenlos starten →